Skip to main content
Premium Trial:

Request an Annual Quote

Recent Patents of Interest in Proteomics: Jan 24, 2008

US Patent 7,321,829. Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips. Inventors: Jose Remacle; Joseph Demarteau; Nathalie Zammatteo; Isabelle Alexandre; Sandrine Hamels; Yves Houbion; Francoise de Longueville. Assignee: Eppendorf Array Technologies
Invention pertains to a method for identifying and/or quantifying target compounds from samples. The target compound is put into contact with a capture molecule to allow specific binding. The capture molecule is then fixed upon a surface of a solid support, according to an array comprising a density of at least 20 discrete regions per centimeter. Each of the discrete regions is fixed with one species of capture molecules. A precipitate is formed at the binding site. Precipitates in discrete regions are searched for and correlated with the identification and/or quantification of the target compound.

US Patent 7,320,864. Methods of using molecular constructs for detection of biochemical reactions. Inventor: Jiacheng Yang. Assignee: BioArray Solutions
Invention pertains to molecular constructs and methods of their use in detecting biochemical reactions. In particular, the molecular construct has a capture portion and a substrate portion “where the capture portion isolates the construct from a sample medium, and the substrate portion enables the construct to be acted upon and undergo a physical change, which can be detected and measured,” according to the patent’s abstract.

US Patent 7,319,012. Protein arrays and methods and systems for producing the same. Inventors: Philip Felgner; Denise Doolan. Assignee: Gene Therapy Systems
Invention describes methods of generating and analyzing a plurality of polypeptides. Libraries and arrays of polypeptides are assayed to determine their individual immunogenic effect. Based on this, specific subunit vaccines can be developed.

US Patent 7,318,907. Surface plasmon enhanced illumination system. Inventors. Peter Stark; Dale Larson. Assignee: President and Fellows of Harvard College
Described are methods and apparatus for the production of small, bright nanometric light sources from “apertures that are smaller than the wavelength of the emitted light,” according to the patent’s abstract. Light is directed at a metal surface layer onto a light barrier that includes at least one aperture directing a small spot of light onto a target. The incident light excites surface plasmons in the top metal surface layer. The energy couples through the aperture to the opposing surface where it is emitted as light from the aperture or the rim of the aperture. The extent to which surface plamsons are induced on the surface of the aperture exit is prevented or severely limited, thereby restricting the resulting emissions to small target areas.

US Patent 7,316,931. Mass defect labeling for the determination of oligomer sequences. Inventors: Luke Schneider; Michael Hall; Robert Petesch. Assignee: Target Discovery
Invention provides mass tagging methods that the inventors say results in greater mass spectrometric sensitivities and molecular discrimination, compared to other existing methods.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.